天康生物(002100.SZ):擬開展與生產經營相關的原材料商品期貨的套期保值業務
格隆匯 11 月 20日丨天康生物(002100.SZ)公佈,公司於2020年11月20日召開第七屆董事會第十一次會議,審議通過了《關於開展商品期貨套期保值業務的議案》,同意公司開展與生產經營相關的原材料商品期貨的套期保值業務。
公司根據2020年-2021年可操作原料的使用規模,預計套期保值業務使用資金不超過人民幣2億元。如擬投入資金有必要超過人民幣2億元的,應將關於增加期貨套期保值投入總額的議案及其分析報告和具體實施方案提交公司董事會審議批準,並按公司《天康生物股份有限公司商品期貨套期保值業務內部控制制度》的規定執行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.